Bausch Health Companies Inc. (NYSE:BHC – Get Rating) saw some unusual options trading on Friday. Stock traders purchased 68,278 call options on the stock. This is an increase of approximately 300% compared to the typical volume of 17,058 call options.
Wall Street Analyst Weigh In
BHC has been the subject of a number of recent analyst reports. Piper Sandler decreased their target price on shares of Bausch Health Companies from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Friday. Royal Bank of Canada increased their target price on shares of Bausch Health Companies from $4.50 to $8.00 and gave the company a “sector perform” rating in a research report on Thursday, September 1st. Truist Financial downgraded shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. Finally, JPMorgan Chase & Co. downgraded shares of Bausch Health Companies from an “overweight” rating to a “neutral” rating in a research report on Thursday, July 28th. Six research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.60.
Bausch Health Companies Price Performance
Bausch Health Companies stock opened at $7.40 on Friday. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of 61.67, a PEG ratio of 0.11 and a beta of 1.21. Bausch Health Companies has a 52-week low of $4.00 and a 52-week high of $29.58. The stock’s 50 day moving average price is $6.84 and its two-hundred day moving average price is $13.23. The company has a debt-to-equity ratio of 85.63, a quick ratio of 0.87 and a current ratio of 1.08.
Hedge Funds Weigh In On Bausch Health Companies
About Bausch Health Companies
Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
- Get a free copy of the StockNews.com research report on Bausch Health Companies (BHC)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.